Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
Valo Health’s $2.8 Billion Merger with Khosla Ventures Acquisition Co.
Repertoire Immune Medicines’ $189 Million Series B Financing
Goodwin Procter LLP advised Repertoire Immune Medicines on the deal. Repertoire Immune Medicines announced the completion of its $189 million Series B financing. Joining Flagship Pioneering, Repertoire’s...
Rubius Therapeutics’ $200 Million Underwritten Public Offering
Goodwin Procter LLP advised Rubius Therapeutics on the deal. Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at...
Aura Biosciences’ $80 Million Financing Round
Goodwin Procter LLP advised Aura Biosciences on the deal. Aura Biosciences announced the closing of its oversubscribed $80 million financing. The financing was led by Matrix Capital...
Tessera Therapeutics’ $230 million Series B Financing Round
Goodwin Procter LLP advised Tessera Therapeutics on the deal. Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised...
Valo Health’s $300 Million Million Series B Funding Round
Goodwin Procter LLP advised Valo Health on the deal. Valo Health announced the final closing of its Series B at $300 million, including a $110 million...